Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing Cognitive Deterioration in COVID-19 (ACDC) Cognitive Impairment After COVID-19 - Inflammatory and Neural Correlates: A Pilot Study

NCT05855434 is registered in ClinicalTrials.gov with NHS Grampian as lead sponsor.

NCT NCT05855434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05855434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing Cognitive Deterioration in COVID-19 (ACDC) Cognitive Impairment After COVID-19 - Inflammatory and Neural Correlates: A Pilot Study
Lead sponsor
NHS Grampian
Phase
Observational
Overall status
Completed
Start date
January 1, 2023
Completion date
July 16, 2024
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive change, cognitive dysfunction, sars-cov-2 infection